Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | TACR1 | P25103 | 5/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | PREP | P48147 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29868206 | 0.93 | CTRB1 (0.56) | CTRB1OPRM1OPRD1OPRK1TACR1 | |
| SCHEMBL6434028 | 0.93 | CTRB1 (0.56) | CTRB1OPRM1OPRD1OPRK1TACR1 | |
| SCHEMBL13743328 | 0.89 | FAP (0.49) | ATML3MBTL1OPRM1OPRD1OPRK1 | |
| SCHEMBL30429187 | 0.89 | CTRB1 (0.51) | CTRB1OPRM1OPRD1OPRK1TACR1 | |
| SCHEMBL13700380 | 0.87 | ITGB1 (0.49) | CTRB1ATMTACR1NPSR1ALDH1A1 | |
| SCHEMBL12084457 | 0.86 | CTRB1 (0.43) | CTRB1L3MBTL1GAAOPRM1OPRD1 | |
| SCHEMBL30595564 | 0.86 | CTRB1 (0.50) | CTRB1OPRM1OPRD1OPRK1ACE | |
| SCHEMBL29749447 | 0.85 | CTRB1 (0.48) | CTRB1L3MBTL1NPSR1 | |
| SCHEMBL29706288 | 0.84 | CTRB1 (0.55) | CTRB1L3MBTL1NPSR1 | |
| SCHEMBL30317756 | 0.84 | CTRB1 (0.49) | CTRB1L3MBTL1GAANPSR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9243028-B2 | Facile amide formation via S-nitroso thioacid intermediates | WASHINGTON STATE UNIVERSITY (US) | 2016-01-26 | — | — | US | disclosed |
| US-20120190820-A1 | FACILE AMIDE FORMATION VIA S-NITROSO THIOACID INTERMEDIATES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-07-26 | — | — | US | disclosed |
| US-20090215093-A1 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190820-A1 | FACILE AMIDE FORMATION VIA S-NITROSO THIOACID INTERMEDIATES | NAAA, TST, ASNS | CTRB1 1613/4885ATM 2526/4885L3MBTL1 2874/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.